Ad Header

PharmaLive

Slogan

The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Researchers find alarming rise in cost of MS drugs over past two decades

PORTLAND, Ore., April 24, 2015 /PRNewswire/ — A new study shows an “alarming rise” over the last 20 years in the costs of drugs used to slow the progression of multiple sclerosis or reduce the frequency of attacks, according to a study led by researchers at Oregon Health & Science University (OHSU) and Oregon State University […]

Read More »

Expanding Naloxone use could reduce drug overdose deaths and save lives

ATLANTA, April 24, 2015 /PRNewswire-USNewswire/ — Allowing more basic emergency medical service (EMS) staff to administer naloxone could reduce drug overdose deaths that involve opioids, according to a Centers for Disease Control and Prevention (CDC) study, “Disparity in Naloxone Administration by Emergency Medical Service Providers and the Burden of Drug Overdose in Rural Communities,” published […]

Read More »

Bristol wins EU green light for immune system cancer drug

(Reuters) – European regulators have recommended approval of Bristol-Myers Squibb’s Opdivo, paving the way for it to become the first of a closely watched group of immune system-boosting cancer medicines to go on sale in Europe. The drug, also known as nivolumab, was given a green light on Friday by the European Medicines Agency (EMA) […]

Read More »

Novo launches Saxenda in US, sees more launches in 2015

(Reuters) – Novo Nordisk has launched its Saxenda obesity drug in the United States, it said on Wednesday, a long-awaited milestone that will provide a new revenue stream for the Danish drugmaker. The company has said previously it expects sales from the drug to eventually reach $1 billion a year. It said in a statement […]

Read More »

MMR vaccine not linked to autism, even in high-risk kids

(Reuters Health) – The measles, mumps and rubella (MMR) vaccine is not linked to development of autism spectrum disorders, even among children considered to be at risk, a large new study finds.  Among nearly 100,000 children, receipt of the MMR vaccine did not increase the risk for autism spectrum disorder (ASD), regardless of whether kids […]

Read More »

Indian parliamentary committee recommends price caps for all drugs

(Reuters) – An Indian parliamentary committee has recommended that price caps should be extended to all drugs in the country and that the government should expedite the capping process. Indian law allows the National Pharmaceutical Pricing Authority (NPPA) regulator to fix prices of drugs on a list of essential medicines, thereby keeping prices in check […]

Read More »

GlaxoSmithKline Recalls Flu Vaccine Over Potency Issues

U.K.-based GlaxoSmithKline (GSK) announced on April 14, 2015 that it was recalling all remaining lots of its 2014-2015 Flulaval Quadrivalent flu vaccine. The company noted that two of the components of the vaccine, the B strains, appeared to have lost potency below the minimum specifications. The potency issue, according to the company, the U.S. Centers […]

Read More »

Oasmia’s Lead Cancer Product Paclical Receives Market Approval in the Russian Federation

UPPSALA, Sweden, April 20, 2015 /PRNewswire/ — Paclical, a novel formulation of paclitaxel based on Oasmia’s XR-17 technology, was approved for treatment of (i.e., it received market authorization for) epithelial ovarian cancer in combination with carboplatin. XR-17 is non-toxic and forms water soluble nanoparticles with paclitaxel.      (Logo: http://photos.prnewswire.com/prnh/20150420/740096 )  The Russia-based company Pharmasyntez holds the […]

Read More »

Lupin Launches Zaxine in Canada

MUMBAI and MONTREAL, April 20, 2015 /PRNewswire/ — Zaxine 550mg (rifaximin) is a long term antibiotic treatment for adults living with hepatic encephalopathy (HE), a complication of liver disease (cirrhosis). HE can lead to a wide spectrum of mental and physical symptoms, including confusion, disruption in sleep patterns, personality changes and coma Zaxine® 550mg has approved by […]

Read More »

Teva to pay $512 million to settle claims of delayed generic Provigil

(Reuters) – Teva Pharmaceutical Industries Ltd has agreed to pay $512 million to settle a class action claiming that Cephalon Inc, which Teva bought in 2011, used anticompetitive settlements to delay generic versions of its wakefulness drug Provigil, according to court papers. The settlement is the largest ever to be paid to drug buyers that […]

Read More »

Ad Right Top

MedAdNews

Extensive pharmaceutical business and marketing intelligence. For back issues, please contact MDAD@kmpsgroup.com.

February 2019 Focus: Agenda 2019, Top 10 Pipelines To Watch, Value Of Pharmaceuticals, and more!

Subscribe

Ad Right Bottom